Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
“ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to ...
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
Dec 20, 2024 · "ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic...
Vertex Announces US FDA Approval of ALYFTREK - Business Wire
Dec 20, 2024 · Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor
Vertex Announces US FDA Approval of ALYFTREK™, a Once
6 days ago · Elevated transaminases have been observed in patients treated with ALYFTREK. Cases of serious and potentially fatal drug-induced liver injury and liver failure were reported in patients taking a fixed-dose combination drug containing elexacaftor, tezacaftor, and ivacaftor, which contains the same or similar active ingredients as ALYFTREK.
Alyftrek Gets FDA Approval for Cystic Fibrosis - Clinical Advisor
2 days ago · Vertex announces US FDA approval of Alyftrek TM, a once-daily next-in-class CTFR modulator for the treatment of cystic fibrosis. News release. Vertex Pharmaceuticals. December 20, 2024.
FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for …
Elevated transaminases have been observed in patients treated with Alyftrek. Cases of serious and potentially fatal drug-induced liver injury and liver failure were reported in patients taking a fixed-dose combination drug containing elexacaftor, tezacaftor, and ivacaftor, which contains the same or similar active ingredients as Alyftrek.
Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval
Dec 20, 2024 · (RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis. Alyftrek is a once-daily ...
FDA Approves Alyftrek, Once-Daily CFTR Modulator for Cystic …
Dec 21, 2024 · SKYLINE 102. Trial Name: A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/ MF) ClinicalTrials.gov ID: NCT05033080 Sponsor: Vertex Pharmaceuticals Incorporated Completion Date: November 21, 2023 SKYLINE 103. Trial Name: A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF ...
Vertex wins FDA nod for once-daily cystic fibrosis triplet
5 days ago · Vertex has priced Alyftrek at a list price of $370,269 per year, which is 7% higher than Trikafta’s annual wholesale acquisition cost of $346,048, according to a securities filing.
Vertex announces FDA approval of Alyftrek | Markets Insider
Dec 20, 2024 · Vertex Pharmaceuticals (VRTX) announced that the U.S. Food and Drug Administration has approved Alyftrek, a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance...
- Some results have been removed